Evidence map›Paper›PMID 16222314›Full record

ArticleBritish journal of cancer2005

Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats.

H Uchino, Y Matsumura, T Negishi, F Koizumi, T Hayashi, T Honda, N Nishiyama, K Kataoka, S Naito, T Kakizoe

Registry-linked trialOpen access · hybridAbstract readComparative Study
In one paragraph

Article in British journal of cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00910741 (Phase I/II Study of the Combination Therapy With NC-6004 and Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer in Asian Countries), which is not on this map. Cited by 105 papers.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00910741 phase1 / phase2completednot on this mapstarted 2009, after this paper: background citation

Phase I/II Study of the Combination Therapy With NC-6004 and Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer in Asian Countries

TypeinterventionalSponsorNanoCarrier Co., Ltd.Ran2009 to 2013Enrolled40ConditionsLocally Advanced and Metastatic Pancreatic CancerArmsNanoplatin (NC-6004) and Gemcitabine
3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 421 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Metallic nanomedicine in cancer immunotherapy.Acta pharmaceutica Sinica. B · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Self-Folding Macromolecular Drug Carrier for Cancer Imaging and Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

H UchinoInvestigative Treatment Division, National Cancer Center Research Institute East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
Y Matsumura
T Negishi
F Koizumi
T Hayashi
T Honda
N Nishiyama
K Kataoka
S Naito
T Kakizoe
National Cancer Center Hospital East · JPThe University of Tokyo · JPFukushima Medical University · JPKyushu University · JPNanoCarrier (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In spite of the clinical usefulness of cisplatin (CDDP), there are many occasions in which it is difficult to continue the administration of CDDP due to its nephrotoxicity and neurotoxicity. We examined the incorporation of CDDP into polymeric micelles to see if this allowed the resolution of these disadvantages. Cisplatin was incorporated into polymeric micelles through the polymer-metal complex formation between polyethylene glycol poly(glutamic acid) block copolymers and CDDP (NC-6004). The pharmacokinetics, pharmacodynamics, and toxicity studies of CDDP and NC-6004 were conducted in rats or mice. The particle size of NC-6004 was approximately 30 nm, with a narrow size distribution. In rats, the area under the curve and total body clearance values for NC-6004 were 65-fold and one-nineteenth the values for CDDP (P<0.001 and 0.01, respectively). In MKN-45-implanted mice, NC-6004 tended to show antitumour activity, which was comparable to or greater than that of CDDP. Histopathological and biochemical studies revealed that NC-6004 significantly inhibited the nephrotoxicity of CDDP. On the other hand, blood biochemistry revealed transient hepatotoxicity on day 7 after the administration of NC-6004. Furthermore, rats given CDDP showed a significant delay (P<0.05) in sensory nerve conduction velocity in their hind paws as compared with rats given NC-6004. Electron microscopy in rats given CDDP indicated the degeneration of the sciatic nerve, but these findings were not seen in rats given NC-6004. These results were presumably attributable to the significantly reduced accumulation of platinum in nerve tissue when NC-6004 was administered (P<0.05). NC-6004 preserved the antitumour activity of CDDP and reduced its nephrotoxicity and neurotoxicity, which would therefore seem to suggest that NC-6004 could allow the long-term administration of CDDP where caution against hepatic dysfunction must be exercised.

Indexed as

MicellesAnimalsAntineoplastic AgentsBody WeightBrainCisplatinDrug CarriersFemaleHumansKidneyKidney DiseasesLiverMiceMice, Inbred BALB CMice, NudeNeurotoxicity SyndromesAntineoplastic AgentsCisplatinDrug CarriersMicellesPolyethylene Glycols

Identifiers

PMID16222314
PMCPMC2361620
OpenAlexW1974920077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.